Learned stromal expression score associates with colon-cancer outcomes
Source check: Source checked. Not independent scientific confirmation.
Finding: A 31-gene score selected using elastic-net and penalized survival learning was associated with worse relapse-free and overall survival in retrospective colon-cancer data. A higher score also showed adverse-outcome associations in a separate TCGA cohort. The result is a clinical expression–outcome association, not proof of chemotherapy resistance or a treatment-selection benefit.
Technology: Elastic-net learning; LASSO-Cox feature selection
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Elastic-net models learn stromal-group discriminators, and repeated penalized Cox fits select the expression features that constitute the measured-outcome-associated score.
- Test and result
- The score was developed using five GEO datasets totalling 990 cases and examined in 382 TCGA-COAD cases. Outcome-informed resampling and expression cutoffs selected genes; the final score subtracts the mean expression of negatively signed selected genes from the positive group. The source reports adjusted survival associations.
- Limitation / still unknown
- Prognostic outcomes inform development, selection and cutoffs; derivation-cohort associations are not independent validation. Treatment comparisons are observational and do not identify causal benefit or intrinsic resistance. Computational drug-response and pathway predictions are not measured clinical response. Supplemental implementation and treatment-confounding details were not inspected; separate experimental mechanisms are not represented.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9118126/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Exact primary front and selected computational/clinical Methods and corresponding high-level Results; operational laboratory protocols excluded from review.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.